Indegene Limited
It is a digital-first, life sciences commercialization company. It helps biopharmaceutical, emerging biotech and medical device companies develop products, get them to the market, and grow their impact through the life cycle in a more effective, efficient, and modern way.
What Indegene files
- Others70
- Investor Meet67
- Updates40
- Important23
- JV/Acquisition10
- Board Meeting8
Indegene's UK subsidiary acquired the trade and assets of group company, Trilogy Writing & Consulting, for GBP 190,679. This internal transaction consolidates business operations, with no impact on Indegene's overall ownership or external portfolio.
Indegene has announced a board meeting on Thursday, July 31. The key agenda items include considering the financial results for the quarter ended June 30, 2025. The board will also approve allotments under the ESOP Scheme 2020. This meeting is crucial for investors, providing an update on quarterly performance and...
Indegene Limited has announced a board meeting to approve changes in the utilization of IPO proceeds, subject to shareholder approval via postal ballot. This adjustment follows the Audit Committee's suggestion and aims to optimize the use of funds raised. No immediate financial impact disclosed.
Indegene Limited has announced a board meeting to consider the financial results for the quarter and half-year. The company is reaching out to shareholders without registered emails to provide online access to the Annual Report for FY 2024-25. Shareholders with physical shares are encouraged to update their KYC and dematerialize...
Indegene has announced a board meeting to review the financial results for the quarter and half-year. The company is advancing its ESG goals with targeted reductions in Scope 1, 2, and 3 emissions by 2028. Women make up 46% of its workforce, reflecting strong diversity. Operating in 48 countries, Indegene...